Elagolix
Hormonal / ClinicalAlso known as: Orilissa
Mechanism
The first oral GnRH antagonist — a pill that does what injectable GnRH drugs do. Approved for endometriosis pain and uterine fibroids. The clever part: at lower doses it only partially suppresses estrogen, enough to reduce pain but still preserving enough estrogen to protect bones. Higher doses suppress more completely for more severe symptoms, but add-back therapy can be used for bone protection.
Technical detail
Non-peptide, orally bioavailable GnRH receptor antagonist (small molecule, MW 631). Competitive antagonist at GnRHR on pituitary gonadotropes — dose-dependent suppression of LH, FSH, and consequently estradiol/progesterone. Low dose (150mg QD): partial estrogen suppression (E2 ~40-50 pg/mL) — reduces endometriosis pain while preserving sufficient estrogen for bone maintenance. High dose (200mg BID): near-complete suppression (E2 ~12 pg/mL) — more effective for pain but requires add-back therapy (norethindrone) for bone protection if used >6 months. Oral bioavailability ~32%. Half-life ~4-6 hours (requires BID dosing at high dose). Rapidly reversible: estrogen levels return within days of stopping. Phase 3 ELARIS EM-I/II trials: 46% of women on 150mg QD and 76% on 200mg BID achieved clinically meaningful dysmenorrhea reduction (vs. 20% placebo). ORILISSA approved for endometriosis (2018). Oriahnn (elagolix + E2/NETA add-back) approved for uterine fibroids (2020). Hepatotoxicity risk: ALT elevations in ~1-2%, contraindicated in severe hepatic impairment.
Effects
Elagolix (Orilissa) is an oral, non-peptide GnRH receptor antagonist that produces dose-dependent suppression of pituitary gonadotropins and downstream estrogen production. Unlike GnRH agonists, elagolix causes no initial hormonal flare, and unlike depot GnRH formulations, its short half-life (approximately 4-6 hours) allows rapid reversibility upon discontinuation. The defining pharmacological feature is partial estrogen suppression at lower doses (150 mg once daily), which reduces estradiol to early follicular phase levels (approximately 40-50 pg/mL), versus near-complete suppression at higher doses (200 mg twice daily), which approaches menopausal levels (<20 pg/mL). This dose-dependent estrogen modulation creates a clinically meaningful spectrum. At the lower dose, enough residual estrogen is maintained to preserve bone density while still providing significant relief from estrogen-driven symptoms like endometriosis pain. At the higher dose, more complete estrogen suppression is achieved for conditions requiring near-total hormonal shutdown, such as heavy menstrual bleeding from uterine fibroids, but at the cost of accelerated bone mineral density loss and more pronounced hypoestrogenic symptoms. This graduated approach was a deliberate design choice to allow tailored therapy. Systemic effects of elagolix reflect its estrogen-lowering action: hot flashes, night sweats, mood changes, and headache are common and dose-dependent. Bone mineral density decreases of 1-3% at the lumbar spine over 12 months have been documented at the higher dose, which is less than the 5-8% loss typically seen with depot GnRH agonists over the same period. Lipid profiles may shift unfavorably with estrogen suppression, and hepatic transaminase elevations have been reported, necessitating liver function monitoring.
Practitioner Guide
Elagolix is FDA-approved for moderate-to-severe endometriosis pain (150 mg daily or 200 mg twice daily) and heavy menstrual bleeding from uterine fibroids (300 mg twice daily, co-packaged with hormonal add-back as Oriahnn). The oral route is the primary practical advantage over injectable GnRH agonists like leuprolide depot, eliminating the need for clinic visits for intramuscular injections. Rapid reversibility (estrogen recovery within days of stopping) provides flexibility that 1-month or 3-month depot formulations cannot match. For endometriosis, start with 150 mg once daily. This lower dose provides meaningful pain reduction for most patients while preserving enough estrogen to minimize bone loss and hypoestrogenic symptoms. Reserve the 200 mg twice daily dose for patients with inadequate response, and limit duration at this higher dose to 6 months due to bone density concerns. For fibroids with heavy bleeding (Oriahnn formulation), the 300 mg twice daily dose is combined with norethindrone acetate 0.5 mg and conjugated estrogens 1 mg as hormonal add-back to mitigate bone loss and vasomotor symptoms, allowing use for up to 24 months. Key monitoring includes liver function tests before initiation, as elagolix is a moderate CYP3A inducer and is itself hepatically metabolized (contraindicated in severe hepatic impairment). Bone density assessment is warranted for patients with baseline osteopenia or planned treatment beyond 6 months at higher doses. Compared to injectable GnRH agonists, elagolix offers superior convenience, faster onset and offset, and the bone-sparing advantage of partial suppression, but requires daily adherence and costs significantly more than generic leuprolide. The competitive landscape now includes relugolix combination (Myfembree) for fibroids and linzagolix for endometriosis, both offering similar oral GnRH antagonist mechanisms.
Research Summary
Tier 1 (robust evidence): The Elaris EM-I and EM-II Phase 3 trials established efficacy for endometriosis-associated pain, with both doses demonstrating statistically significant reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo over 6 months. The Elaris UF-1 and UF-2 trials established efficacy for fibroid-related heavy menstrual bleeding, with the add-back combination (Oriahnn) achieving amenorrhea or minimal bleeding in approximately 70% of patients. Bone density data from these trials quantified the dose-dependent BMD loss and confirmed the bone-sparing advantage of the lower endometriosis dose. Tier 2 (solid clinical data): Extension studies out to 12 months confirmed sustained efficacy and characterized the bone density trajectory, showing stabilization of BMD loss with continued treatment and partial recovery after discontinuation. Hepatic safety analyses identified dose-dependent transaminase elevations (generally <3x ULN) and established monitoring recommendations. Pharmacokinetic studies characterized the drug interaction profile, including reduced efficacy of hormonal contraceptives at the higher dose, requiring non-hormonal backup contraception. Tier 3 (emerging/comparative): Cross-trial comparisons with injectable GnRH agonists suggest comparable pain reduction with less bone density loss at the lower elagolix dose, though no head-to-head randomized trials exist. Emerging competition from relugolix combination (Myfembree) and linzagolix provides patients and prescribers with multiple oral GnRH antagonist options, though comparative effectiveness data between these agents are limited. Long-term post-marketing surveillance is building the real-world safety database, particularly regarding hepatic events and bone health outcomes beyond 24 months.